Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246264 | 0.79 | MEN1 (0.44) | MAOAMAOBTAAR1CTBP2 | |
| SCHEMBL1040588 | 0.78 | NOS2 (0.50) | GRIN2BCTBP2 | |
| SCHEMBL201554 | 0.77 | CTBP2 (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3483026 | 0.76 | HTR3E (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14282773 | 0.75 | PNMT (0.60) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Acetamide SCHEMBL27451393 | 0.74 | SIGMAR1 (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Acetic Acid SCHEMBL28193126 | 0.74 | PNMT (0.74) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4781067 | 0.74 | PNMT (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1848 | 0.74 | ALDH1A1 (0.60) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2659547 | 0.73 | ALDH1A1 (0.61) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | HTR3E 992/4885HTR3B 808/4885HTR3A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.